Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

The Company will be focusing on the following programs with Bucillamine: Revive is targeting nerve agent exposure as its initial indication for its medical countermeasures program. Nerve agents are ...